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Abstract
Preeclampsia is a complication of pregnancy primarily characterized by hypertension and proteinuria and affects other organs as 
well . The underlying causes are not yet fully understood . However, it is suggested that angiogenic factors of the placenta, genetic 
factors, a malfunctioning immune system, and oxidative stress all play a role in causing preeclampsia. Currently, the only definitive 
cure known for preeclampsia is delivery of the baby .  Management of the condition includes taking preventative measures as well 
as drugs such as labetalol and MgSO4 . This paper analyzes mechanisms of preeclampsia and determines the possible causes 
and most effective ways to manage the condition .
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Introduction
Preeclampsia (PE) is a multisystem complication that 
occurs during pregnancy and is primarily characterized 
by elevated blood pressure and abnormally high levels of 
protein in the urine.  The disorder manifests itself after the 
20th week of gestation and can lead to serious complica-
tions, possibly even fatality of the mother and the baby.  It 
can also cause long-term health conditions.  The disease 
has a worldwide prevalence of 5-8% of pregnancies and 
currently ranks as one of the leading causes of maternal 
and perinatal morbidity (Pennington et al., 2012).  In ad-
dition to hypertension and proteinuria, afflicted patients 
may undergo other symptoms including edema of the face 
and hands, headaches, dizziness, decreased urination, nau-
sea, and vision changes.  Furthermore, 10-20% of women 
with severe cases of PE can develop a potentially lethal 
condition known as the HELLP syndrome, characterized 
by the fundamental features of “hemolysis, elevated liver 
enzyme levels, and low platelets.”  If PE progressively 
worsens, it can turn into eclampsia, where the elevated 
blood pressure causes the mother to experience seizures 
and may result in a coma (Preeclampsia. 2016). 
The exact etiology of PE remains unknown.  The pur-
pose of this review is to determine the possible causes of 
PE and the most effective therapeutic approaches avail-
able to manage the condition.
Methods
This comprehensive review was conducted based on critical 
analyses of data collected from various databases accessed 
through Touro College’s online library, such as ProQuest 
and PubMed. The National Center for Biotechnology 
(NCBI) website was also a useful tool in providing addi-
tional sources. Key words and phrases used to retrieve 
data include “mechanisms of preeclampsia,” “causes of pre-
eclampsia,” and “management of preeclampsia.”
Discussion
PE can be classified into an early onset and late onset 
form.  Women suffering from early-onset PE are diagnosed 
before their 34th week of pregnancy and symptoms of 
low birth weight and intrauterine growth restriction will 
manifest.  Conversely, the late onset form expresses itself 
after the 34th week and its cause is generally associated 
with various maternal conditions including obesity, diabe-
tes, and chronic kidney diseases.  Regardless of the sub-
type, it is evident in all cases of PE that the placenta plays a 
central role in its pathophysiology (Lisowska et al., 2018). 
In normal pregnancies, an increase in blood flow to the 
uterus will occur to ensure sufficient supply for the in-
tervillous spaces and overall proper fetal development. 
Cytotrophoblasts invade deep inside the maternal spiral 
arteries to establish a vascular network and remodeling 
subsequently takes place to form high-capacity blood ves-
sels. This mechanism is defective in the placentas of indi-
viduals destined to develop PE. In such cases, the cytotro-
phoblasts fail to entirely convert from their proliferative 
epithelial form into their invasive endothelial form. As a 
result, remodeling of the spiral arteries is greatly hindered 
and the restricting maternal vessels will lead to placental 
ischemia (Rana et al., 2019).
Another identifying feature found to be associated with 
the pathogenesis of this disorder is elevated levels of an an-
tiangiogenic protein called soluble fms-like tyrosine kinase 
(sFLT1) in the placenta (Roberts & Bell, 2013). This was 
furthered studied on non-human primates. A group of ani-
mals was induced with uteroplacental ischemia (UPI) while 
a Sham group of animals was not. The concentration of 
plasma sFLT1 of both animal groups was measured over a 
two-week period and the results were compared. As seen 
in Figure 1, the UPI animals showed a significant increase 
in sFLT-1 over time, whereas the Sham group’s sFLT1 levels 
remained roughly unchanged (Makris et al., 2007). This ex-
periment shows how reduced blood flow directly increas-
es the amount of circulating sFLT1 in the plasma.
SFLT-1 is a soluble receptor that binds to the angiogen-
ic factors, vascular endothelial growth factor (VEGF) and 
placental growth factor (PlGF), and inhibits them from in-
teracting with their receptors, Flt1 and Flk1. When they 
cannot bind to their receptors, the angiogenic factors are 
incapable of carrying out their function of promoting the 
growth of new blood vessels. Therefore, the presence of 
sFLT1 inhibits the growth of blood vessels. In PE, the exces-
sive amount of sFLT1 abnormally constricts the mother’s 
blood vessels, leading to hypertension, in addition to affect-
ing the function of various other organs. The constricted 
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blood vessels are also responsible for causing the kidneys 
to release proteins into the urine (Roberts & Bell, 2013).
Etiology of PE
The causes of placental malformation are still being re-
searched and currently remain unclear. It is understood, 
however, that anything causing oxidative stress to the 
placenta is likely to cause PE. Oxidative stress is when 
there is an imbalance between reactive oxygen species 
(ROS) and antioxidants which disrupts metabolism and 
cell signaling in aerobic organisms.  Several cell compart-
ments can produce ROS, such as the mitochondria, endo-
plasmic reticulum, and nuclear membrane. They produce 
O2•− anions as a byproduct of auto-oxidation during the 
electron transport chain. ROS can also be produced as a 
result of arachidonic acid metabolism. Oxidative stress 
regulates the transcription factors NRF2 and FoxO which 
control the expression of genes that detoxify oxidizing 
molecules. Thus, the imbalance causes an interruption in 
the detoxification process and can lead to structural and 
physiological damage to DNA, RNA, proteins, and lipids. 
(Auoache et al., 2018). Oxidative stress is known to cause 
endothelial cell dysfunction which can contribute to PE 
(Duhig et al., 2016).
Risk Factors for PE
Several principle risk factors were found to be associated 
with the onset of PE. The presence of certain medical con-
ditions can make a woman more prone to developing PE. 
Hypertension has strongly proven to be correlated with 
an increase in one’s risk of developing PE. To be diagnosed 
with hypertension, there must be a “systolic 
blood pressure greater than or equal to 140 
mmHg and/or diastolic blood pressure great-
er than or equal to 90 mmHg” (Hinkosa et al., 
2020). A retrospective study of the databases 
from two hospitals identified 362 women 
who had chronic hypertension that required 
treatment prior to their pregnancies were 
analyzed. The data revealed that the percent-
age of superimposed PE in these women was 
23.2%, a percentage notably higher than that 
of the general population. (Lecarpentier et al., 
2013).
Autoimmune diseases like systemic lupus 
erythematosus and antiphospholipid anti-
body syndrome, diabetes type 1 or 2, and 
chronic arterial hypertension are other con-
ditions classified as high-risk factors for PE 
(Mayrink et al., 2018). 
Other risk factors known to be linked 
with PE include nulliparity, maternal age over 35, multi-
fetal pregnancy, prior case of PE, chronic kidney disease, 
prior stillbirth, and a pre-pregnancy BMI over 25. Data 
was extracted and pooled from 92 studies regarding the 
relative risk of developing PE for women with each risk 
factor. Pooling of the data is helpful in bringing about re-
sults that are as reliable as possible. 
Genetic Factors
Currently, there are no identified genes that are direct-
ly responsible to cause the disorder. However, because 
clustering of PE among families is common, it is suggest-
ed that there must be a genetic etiological component 
involved. Women with a first relative that developed PE 
have a three to five-fold increased risk of getting it as 
well (Hansen et al., 2018). There is also research suggest-
ing that paternal genes may be a contributing risk factor 
for the development of PE as well. Women who became 
pregnant from a man that has had a previous partner with 
preeclampsia were seen to be at a slightly higher risk for 
PE (Galaviz-Hernandez et al., 2018).
Mother’s Immune Responses
PE is thought to be a disorder that may be due to mal-
functioning of the mother’s immune system. The syncytial 
surface of the placenta sheds particles, ranging from large 
deported multinuclear fragments to sub-cellular com-
ponents, and it is suggested that these particles contain 
proteins that trigger an inflammatory response.  In PE, the 
number of circulating particles present increases, indicating 
a relationship between excess particles and the pathology 
Figure 1: The concentration of plasma sFLT1 levels are significantly elevated in the UPI 
group in comparison to the sFLT1 of the Sham group (Makris et al ., 2007) .
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of the disease. Thus, preeclampsia is characterized by an 
exaggerated inflammatory response (Palei et al., 2013). 
Furthermore, complications of the maternal immunity 
mechanisms can be a causing factor of PE. During pregnan-
cy, it is essential for the mother’s regulatory CD4 + T cells 
to interact with the uterine natural killer cells in order to 
recognize and accept the fetal antigens and enable placen-
tal growth. Failure of this process leads to a spontaneous 
miscarriage, while a partial failure leads to poor placenta-
tion and dysfunction of the placental perfusion and chronic 
immune activation that stems from the placenta. Women 
with PE were found to have decreased levels of circulating 
regulatory CD4 + T cells. Additionally, they have increased 
levels of T helper 17 cells, cells that are also upregulated in 
various autoimmune disorders (Palei et al., 2013).
Possible Complications of PE During Pregnancy
When symptoms of PE become severe, it can lead to 
dangerous complications for both the mother and the 
fetus, including fatality. Severe PE is when one or more of 
the following conditions is present: blood pressure of 160 
mmHg or higher for systolic and 110 mmHg diastolic on 
at least two occasions that are at least 6 hours apart, at 
least 2 g of proteinuria in a 24 urine specimen or on two 
urine samples collected at least 4 hours apart, oliguria of 
less than 500 mL in 24 hours, cerebral or visual issues, 
pulmonary edema, pain in the epigastric or right upper 
quadrant, fetal growth restriction, a persistent and severe 
headache, or medical issues involving acute renal insuffi-
ciency, hepatic hematoma, and HELLP syndrome (Nankali 
et al., 2013). It is said that 25% of PE cases are classified as 
severe (Minire et al., 2013). 
The mother may develop HELLP syndrome, which 
causes mortality in 25% of affected women. This can bring 
about a variety of complications that can affect many dif-
ferent organ systems such as the central nervous system, 
renal system, respiratory system, and liver. Complications 
include stroke, cerebral edema, retinal blindness, pulmo-
nary edema, laryngeal edema, jaundice, renal failure, liver 
failure, HELLP syndrome, and eclampsia. Globally, pre-
eclampsia and eclampsia are responsible for 10-15% of all 
maternal deaths (Nankali et al., 2013)
As for the fetus, the baby is often deprived of receiving 
a sufficient amount of blood and does not get the oxygen 
and nutrients it needs. Development under such condi-
tions will be hindered, and the baby will have fetal growth 
restriction, causing it to be very small at birth. Often, these 
babies will need to be hospitalized for a period following 
their birth. A stillbirth can happen if the placenta sepa-
rates from the uterine wall, causing the mother to heavily 
bleed. This is more likely to happen if the mother has a 
more severe case of PE, including the HELLP syndrome 
(Preeclampsia research at the NICHD.2012). Infants 
whose mothers had PE during their pregnancy also have 
an increased risk of developing some long-term health 
conditions due to the lack of proper development, such 
as “learning disorders, cerebral palsy, epilepsy, deafness, 
and blindness. Later on, they may be at risk for diabetes, 
congestive heart failure, and hypertension. Infant death is 
also a possible occurrence (Preeclampsia research at the 
NICHD.2012).
Management Options for PE
Because of the severity of the complications that pre-
eclampsia may cause, women should take several precau-
tions to help lower their risk of developing the disorder. 
Antiplatelet drugs, primarily low dose aspirin, are useful 
preventative agents as they reduce the risk of PE by 19% 
as well as decreasing the risk of stillbirth or neonatal death 
by 16% (Duley et al., 2006). Aspirin is effective because it 
reduces platelet aggregation, but it is also a risk of in utero 
cerebral hemorrhage (Atallah et al., 2017). It is advised 
that women at high risk should begin taking this before 
12 weeks until 36 weeks of gestation (English et al., 2015).
Calcium supplementation during pregnancy also ap-
pears to reduce the risk of hypertensive disorders in 
pregnancy, including PE. A group of 579 women were 
assigned as a placebo group and a group of 588 women 
were given calcium supplementation. When comparing 
the percentage of hypertensive disorders of pregnancy 
in the placebo and calcium groups of women, the calci-
um group had a significantly lower risk of hypertensive 
disorders, particularly after the 28th week of gestation. 
There seem to be no side effects associated with calcium 
supplementation (Belizan et al., 1991).
There is also some research suggesting that antioxidant 
supplementation of vitamins C and E may be useful in 
lowering one’s risk of PE.  These agents are thought to 
prevent ROS from inflicting oxidative damage and overall 
restoring the redox equilibrium. This therapy aims to ul-
timately prevent endothelial cell dysfunction, which is an 
important pathological feature of PE (Aouache R. et al., 
2018). However, there are studies that show contradic-
tory results about the effectiveness of these supplements 
on reducing risks of PE. To test their outcomes related 
to PE, women who were 9 weeks to 16 weeks pregnant 
were examined until delivery. 5,088 women were given 
daily antioxidant supplementation of vitamins C and E, 
whereas 5,066 women served as a placebo group. The 
vitamins did not have much of an effect on the risk of de-
veloping PE. Based on such findings, they do not seem to 
serve any significant preventative purpose (Preeclampsia 
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Research at the NICHD 2012).
Early and accurate detection of the disorder is im-
portant in order to provide immediate optimal man-
agement. Therefore, closely monitoring changes in preg-
nancy, especially for women who classify as high-risk, is 
recommended. Regularly assessing blood pressure can 
catch any hypertension which is a good indicator of 
PE (Mayrink et al., 2018). Consistent urinary analyses 
should be performed in order to check for proteinuria, 
another big marker of PE. Monitoring growth often is 
useful in identifying signs of fetal growth restriction as 
well (English et al., 2015). 
It is certain that the only definitive cure for PE is 
delivery. The decision to deliver the fetus prematurely 
is often based on two factors, estimated fetal weight 
and the severity of the disorder. If the mother is ex-
periencing “uncontrolled severe hypertension that is 
not responding to therapy, eclampsia, acute pulmonary 
edema, abruptio placentae, subcapsular hepatic hemato-
ma, or thrombocytopenia <50,000/mm3 ”, then that in-
dicates a need for immediate delivery (Uzan et al., 2011). 
Nevertheless, there are various ways to help control the 
condition during the pregnancy. Premature birth of the 
fetus is almost always inevitable, since the mother will 
most likely be unable to survive the full pregnancy peri-
od due to her destructive conditions. However, it is ideal 
to allow the baby to develop for as long as possible to 
improve neonatal outcomes. Mainly, it is important to 
allow the fetal lungs to mature. Prolonging treatment 
for as much as possible will result in the most beneficial 
outcome for the fetus (Le et al., 2019).
If blood pressure reaches the level of 160/110 mmHg 
or higher, antihypertensive treatment is a necessity as this 
is considered a medical emergency. Oral antihypertensive 
medications such as labetalol, methyldopa, and nifedipine 
should be administered. If the oral therapy fails to elicit 
a response, intravenous medication such as a labetalol 
infusion or hydralazine should be given. However, the 
commencement of treatment may result in a drop in 
blood pressure that can affect uteroplacental circulation 
and cause fetal distress; hence, the dosage of these drugs 
should be titrated gradually (English et al., 2015).
Magnesium sulfate (MgSO4) is a drug that aids in pre-
venting eclampsia. The drug should be administered to 
women at high risk for eclamptic seizures. It has also been 
shown to lower the risk of cerebral palsy in the offspring. 
MgSO4 does have some adverse effects and can lead to 
paralysis, an absence of reflexes, a lower respiratory rate, 
and arrhythmias. Therefore, patients will need to have 
their pulse, respiratory rate, and reflexes continuously 
monitored in the time following. In the case that toxicity 
does occur, it can be corrected by giving the patient calci-
um gluconate (English et al., 2015).
Conclusion
PE is a disorder that is not fully understood yet. Due to 
the limited knowledge of its precise mechanisms, it remains 
difficult to determine the exact etiology of the disorder. 
However, the reviewed research articles were all consis-
tently in agreement that women with the disease have 
a common pathophysiological finding.  Elevated levels of 
sFLT1 are present in the placenta, which suggests the dis-
ease is largely due to dysfunctional angiogenic factors. The 
inability of the mother’s angiogenic factors to bind to their 
correct receptors causes her blood vessels to constrict 
and leads to manifestations of PE (Roberts & Bell, 2013). 
This seems to be the major factor behind the disorder. 
PE does not have any known cures; the only way to 
successfully stop the disease would be to terminate the 
gestation period and deliver the baby. The goal would 
be to manage and prolong the pregnancy for as long as 
possible in a way that takes both the mother’s and fetus’ 
safety into account (Uzan et al., 2011). After reviewing 
the various treatment options available, it seems that a 
combination of therapeutic agents would be the most 
viable approach for PE. Taking low-dose aspirin is a useful 
protecting drug as it reduces platelet aggregation (Atallah 
et al., 2017). Anti-hypertensive medication is essential 
to control the mother’s blood pressure in cases when 
it reaches 160/110 mmHg or higher. The use of anti-hy-
pertensives can lead to a sudden drop in blood pressure 
that can cause fetal distress, so it is important to respon-
sibly monitor women’s blood pressure when they are on 
these medications. Additionally, MgSO4 is important for 
preventing or treating seizures in eclampsia (English et al., 
2015). Side effects that may present include paralysis, an 
absence of reflexes, a lower respiratory rate, and arrhyth-
mias. However, the drug is vastly advantageous, and moni-
toring the patient and regulating drug administrations will 
eliminate most of the harm it can cause (English et al., 
2015). Knowledge of the various factors that put women 
at high risk for PE is also useful for preventative care. 
Women should have their blood pressure monitored to 
check for hypertension, and urinalyses monitored to look 
for proteinuria, two major symptoms of PE. (Mayrink et 
al., 2018). Taking these steps can help in early detection 
and management of PE.
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